. Adverse events (AEs) were mostly mild-to-moderate in severity. The ability to tolerate doses >1000 mg and safety beyond the initial maintenance period has not been established and initial findings from the ongoing study are reported. METHODS: PALISADE completers were eligible to enter the follow-on study and continue AR101 daily maintenance for 6 months before the next DBPCFC, which included an additional 2000 mg challenge dose. AEs and discontinuations were recorded and compared to the prior 6-month maintenance period. RESULTS: 117 of 316 (37%) AR101-treated PALISADE subjects enrolled in the daily maintenance regimen; the remainder were assigned to other dosing regimens (not included in this analysis). 100 (85%) subjects have completed the DBPCFC to date. AEs, regardless of causality, were similar during both maintenance periods (PALISADE 88% vs follow-on 81.2%). Three subjects (2.6%) discontinued due to AEs, 2 were treatmentrelated (1 EoE, 1 mild systemic reaction). The median tolerated dose was 1000mg with 49% of subjects to date being able to tolerate the highest challenge dose of 2000mg. Of the subjects who tolerated <1000 mg at PALISADE exit, 64% (27/42) could tolerate a higher challenge dose after extended maintenance. CONCLUSIONS: 300 mg daily of AR101 was well tolerated in the ongoing follow-on study; the majority of subjects could tolerate higher challenge amounts (1000 mg and 2000 mg) of peanut protein after additional maintenance. The oligosaccharide a-Gal has recently emerged as a regionally important cause of a syndrome of IgE-mediated delayed anaphylaxis to mammalian meat; however, other allergens can also contribute to meat allergy. We sought to describe subjects who were evaluated for suspicion of mammalian meat allergy but who tested negative for IgE to a-Gal. METHODS: As part of an IRB-approved observational study, 254 patients with histories of suspected allergic reactions (urticaria and anaphylaxis) to mammalian meat were enrolled from central Virginia. Serum was obtained and subjects completed detailed questionnaires. Assays were conducted for total IgE, as well as specific IgE (sIgE) to aGal, cat, beef, pork, gelatin, cat serum albumin, bovine serum albumin and pork serum albumin using standard ImmunoCAP assays. RESULTS: Using a cut-off of 0.35 IU/mL, sIgE to a-Gal was detected in 238 of the 254 subjects. Of the 16 remaining subjects, 10 (63%) described onset of symptoms occurring > _ 2 hrs after mammalian meat ingestion. Specific IgE testing supported a diagnosis of pork-cat syndrome in 3 subjects (sIgE detected to cat, pork and cat serum albumin > _ 0.1 IU/mL), 5 were found to have low-titer a-Gal sIgE (ie, 0.1-0.34 IU/mL) and 3 had detectable sIgE to beef (> _ 0.1 IU/mL) suggestive of primary beef allergy. CONCLUSIONS: In central Virginia sIgE to a-Gal is a common cause of anaphylaxis to mammalian meat, however other causes such as pork-cat syndrome, primary beef allergy, and gelatin allergy should also be considered. , and Krzysztof Rutkowski, MD, MRCP 1 ; 1 Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 2 King's College London, London, United Kingdom. RATIONALE: Shellfish is a common cause of food allergy with an estimated prevalence at 0.5-2.5%. Tropomyosin, the major allergen in shrimp, is currently considered as a cross-reactive panallergen amongst invertebrate species. Crustacean-allergic patients are often co-sensitised to molluscs. METHODS: A retrospective analysis was performed for all open oral food challenges (OFCs) to molluscs conducted at a tertiary UK Allergy Centre from 2011 through 2017. OFCs were offered to patients with primary allergy to crustaceans in the absence of probable reactions to molluscs or a concrete history of recent exposure. Crustacean allergy was diagnosed based on strong history of reactivity with confirmatory positive skin prick tests (SPTs) and/or serum specific IgE (sIgE). RESULTS: Twenty crustacean-allergic patients who had negative OFCs to molluscs were identified (pass rate 100%). OFCs were performed to bivalves (40%), cephalopods (15%) or both classes (45%). Concurrent atopy was prominent. SPTs and/or sIgE were positive to bivalves (mussel 45%, oyster 40%, scallop 45%) and cephalopods (squid 45%, octopus 20%). CONCLUSIONS: Co-sensitisation to molluscs is common in patients with primary allergy to crustaceans. In the absence of a concrete history of exposure or recent reactions, OFCs to molluscs should be considered to avoid unnecessary dietary restriction. Clinical reactivity between crustaceans and molluscs may be less than expected based on immunologic cross-reactivity.
